Thursday, July 9, 2026

pharma · Parkinson's Disease · PARKINSON DISEASE (Disorder) · SER

Serina Therapeutics

Serina Therapeutics clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Huntsville, USA HQ
2007 Founded
23 Employees
Public company Type
SER · NYSE Ticker
Company details
Status
Public
HQ
Huntsville, USA
Founded
2007
Employees
23
Programs
2
Drugs
3
Patents
25
Intelligence · Clinical Programs

Serina Therapeutics projects

2 ClinicalTrials.gov programs sponsored by Serina Therapeutics.

Serina Therapeutics has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. SER-214

    Serina Therapeutics

    Parkinson's Disease

    phase 1 small molecule active

    1 trial
  2. SER-252 (PEOZ-apomorphine)

    Serina Therapeutics

    PARKINSON DISEASE (Disorder)

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Serina Therapeutics have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.